TOPIC

Biomedicine: Industry Trends

Related Topics:
Biomedicine: Industry Trends
Learn about China’s biomedical breakthroughs, from cutting-edge pharmaceuticals to life-saving research, driving global health innovation.
Chinese biotech firms set to crack the global market within a decade, according to industry experts. Photo: Getty Images
China manufacturing

China’s biotech firms may see ‘major breakthroughs’ within a decade. Here’s why

Strong manufacturing base a driving force behind overseas expansion, but industry leaders and analysts say hurdles remain.

videocam
Made in China 2025

China’s Fosun Pharma unit strikes US$2.1 billion obesity drug deal with Pfizer

China economy

Opinion | How China engineered the rapid rise of its drug innovation industry

videocam
Biomedicine: Companies

China’s clinical trial capacity matches US, attracts more global pharma firms

Growth of innovative clinical trials suggests that Chinese biotech firms’ pipeline of novel drug candidates is expanding, analysts say.

China had 2,694 new clinical trials in 2024, up 13 per cent from a year earlier. Photo: Shutterstock
New medical drugs

6 of the best: the billion-dollar biotechs putting China on the map

China’s biotech renaissance is gathering pace as home-grown innovators strike billion-dollar licensing deals with global giants.

Biomedicine: Companies

China biotech forum bills antibody cancer drugs as next-generation treatment

Biotech insiders tout antibody-drug conjugates as the next big thing in cancer treatment, with firms urged to pursue global strategies.

Advertisement
Advertisement
Advertisement
Greater Bay Area

BeOne Medicines to expand cancer-drug offerings in Hong Kong

Fresh off a profitable half year, a global drug company that started as an R&D firm in Beijing plans to expand production in Guangzhou.

A facility manufacturing cancer drugs in Guangzhou. Photo: Handout
Hong Kong stock market

China’s Akeso gets share boost as data shows cancer drug’s benefits

Lung-cancer drug ivonescimab is ‘potentially two to three years ahead of competitors’, analyst says.

HKEX

HKEX’s new Hang Seng Biotech Index Futures to debut next month

The futures contracts platform aims to meet offshore investors’ heightened interest in Hong Kong-listed Chinese biopharmaceutical stocks.

Biomedicine: Companies

Hong Kong MRI maker Time Medical seeks site to boost output, eyes IPO

Aiming to grow sales to US$300 million in 2027, the company is eyeing a Nasdaq IPO and then a Hong Kong secondary listing.

Ma Qiyuan, Time Medical Systems co-founder and chairman, pictured with one of the company’s scanners in its facility in Tai Po on October 6, 2025. Photo: Jonathan Wong
China’s private sector

‘Quantity to quality’: what China’s next 5-year plan means for foreign investors

Beijing has pledged to open up even more to foreign investment. But some officials are becoming more selective about the projects they want.

videocam
Illustration: Brian Wang
Biomedicine: Companies

Mirxes wins China’s approval to launch groundbreaking gastric cancer blood test

The non-invasive blood test helps in the early detection of the fifth leading cause of cancer deaths globally.

Health & Fitness

Li Ka-shing-backed focused ultrasound therapy treats 1 millionth case

The therapy, which uses ultrasound energy to treat a number of diseases including cancer, is gaining global traction, a US expert says.

United States

China’s pharmaceutical sector surges amid growth in sales, licensing income

Strong growth momentum and global push expected to continue, HSBC says.

Chinese pharmaceutical companies’ licensing deals made up about 50 per cent of the total value of such transactions worldwide in the first eight months of the year. Photo: Shutterstock
Biomedicine: Policy

China’s drug developers stretch to become a global force

Although a start-up’s recent triumph is seen as a ‘DeepSeek moment’, domestic players still trail world-beating pharma firms, experts say.

10
Illustration: Henry Wong
Baidu

Baidu-backed drug discovery start-up Biomap challenges Google’s AlphaFold

Biomap expects to double its revenue this year, co-founder and CEO Wei Liu says.

Biomedicine: Geopolitics

Trump’s tariffs on imported drugs ‘not a big concern’ for China’s pharma firms

Chinese drug makers have ‘minimal sales exposure to the US’, Jefferies analysts say.

Advertisement
Advertisement
Advertisement
Biomedicine: Companies

Pfizer’s Metsera acquisition to spur Chinese search for new weight drugs

The deal, worth up to US$7.3 billion, will encourage ongoing investment by mainland players but not draw in new rivals, analysts say.

The Pfizer deal is not good news for Chinese firms developing weight-loss drugs with the aim of reducing injections, an analyst says. Photo: Shutterstock
Health in China

Beijing tackles drug price wars with new tendering rules in anti-involution push

China’s new drug procurement rules prioritise quality over price in a bid to curb cutthroat competition.

Biomedicine: Companies

Ascletis trial shows drug candidate ASC47 boosts semaglutide weight loss effect

Chinese biotech firm is among dozens of mainland drug makers seeking to compete in the global market for diabetes and weight-loss drugs.

Hong Kong stock market

Chinese biotechs get a shot in the arm from policy support, licensing deals

‘We are on an upcycle in the industry and sentiment is very strong,’ Xufunds Investment fund manager Wang Chen says.

Shares of WuXi Biologics have more than doubled year to date. Photo: Shutterstock
US-China tech war

Chinese 3D biomolecule imaging start-up aims for IPO in 2027

Shuimu BioSciences is the first Chinese company to develop its own cryo-electron microscopy machine, a vital tool in drug discovery.

Allen Guo Chunlong, co-founder and CEO Shuimu BioSciences. Photo: Handout
ETFs

Chinese biotech ETFs attract investors amid US$60 billion of licensing deals

Funds from the US are flowing into biotech ETFs as investors seek unique opportunities to beat the market, China AMC’s Heidi Cai says.

Biomedicine: Companies

Chinese biotech firm MGI’s DNA sequencers gaining in the market, BGI CEO says

MGI’s latest product, the DNBSEQ-T7+, can sequence 144 human genomes a day, or one every 10 minutes.

Banking & finance

Global investment funds are tiptoeing into Hong Kong, aided by HKIC

“Geopolitics is not going away any time soon, but smart money needs to invest in the future,” the Hong Kong Investment Corporation’s CEO Clara Chan says.

Pedestrians in Tsim Sha Tsui on August 26, 2025. Photo: Jelly Tse
Banking & finance

China’s healthcare segment eyes record fundraising amid global investor surge

China biotech remains a market bright spot with strong growth, driven by out-licensing, efficiency improvements and cost control.

Investor focus was on companies that address cardiovascular, cancer and other life-threatening conditions. Photo: Shutterstock
China Future Tech briefing

Biomedicine | AI turns China biotechs into drug discovery leaders

Beijing’s push to use artificial intelligence to find new drugs is paying off, with China-based companies earning billions by licensing discoveries to Western firms.

videocam
China technology

China’s biotech industry is gaining on the US. Can tariffs hold them back?

Pharmaceutical firms in China have grown fast, but geopolitics and a long head start could keep US-based leaders at industry apex - for now.

videocam
Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement